These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 16890801)

  • 1. Preclinical and clinical development of novel agents that target the protein kinase C family.
    Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
    Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anticancer drug discovery.
    Buolamwini JK
    Curr Opin Chem Biol; 1999 Aug; 3(4):500-9. PubMed ID: 10419854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia.
    Michie AM; Nakagawa R
    Hematol Oncol; 2006 Sep; 24(3):134-8. PubMed ID: 16841369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of PKCbeta in the malignant tumors and enzastaurin, a PKCbeta inhibitor].
    Li XY; Chen XG
    Yao Xue Xue Bao; 2009 May; 44(5):449-55. PubMed ID: 19618717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells.
    Wang Y; An R; Dong X; Pan S; Duan G; Sun X
    Urol Int; 2009; 82(2):214-21. PubMed ID: 19322013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
    Herbst RS; Oh Y; Wagle A; Lahn M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKC inhibitors: potential in T cell-dependent immune diseases.
    Baier G; Wagner J
    Curr Opin Cell Biol; 2009 Apr; 21(2):262-7. PubMed ID: 19195860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
    Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
    Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The signal transduction pathway of multi-target kinase inhibitors as anticancer agents in clinical use or in phase III].
    Wu W; Lu C; Chen SY; Yu NF
    Yao Xue Xue Bao; 2009 Mar; 44(3):242-57. PubMed ID: 19449520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel targets for cancer chemotherapy].
    Inoue S
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):191-201. PubMed ID: 8611047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model.
    Grant S; Tran P; Zhang Q; Zou A; Dinh D; Jensen J; Zhou S; Kang X; Zachwieja J; Lippincott J; Liu K; Johnson SL; Scales S; Yin C; Nukui S; Stoner C; Prasanna G; Lafontaine J; Wells P; Li H
    Eur J Pharmacol; 2010 Feb; 627(1-3):16-25. PubMed ID: 19850035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
    Mikalsen T; Gerits N; Moens U
    Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key cancer cell signal transduction pathways as therapeutic targets.
    Bianco R; Melisi D; Ciardiello F; Tortora G
    Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS; English JM
    Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.